Strategic Alliance Landmark BioVentures and G.CLIPS Biotech forge strategic alliance to address critical gaps in drug target engagement
Strategic Alliance Landmark BioVentures strengthens immunology and oncology non-clinical capabilities through strategic alliance with Axis Bio
Company Launch Duhn Therapeutics, launched by Landmark BioVentures, signs global license agreement with OM Pharma to further advance clinical-stage, lipid-based cancer immunotherapy
Company Launch SPIMA Therapeutics Launches to Transform Peptide-Based Immunotherapies and Announces Global Licensing Agreement with SATT AxLR